The global genome-wide association study (GWAS) services market was valued at USD 0.94 billion in 2025. The market is estimated at USD 1.04 billion in 2026 and is projected to reach USD 2.47 billion by 2036, at a CAGR of 9.0% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering genotyping and sequencing approaches, imputation and post-GWAS analysis methods, biobank programs, data governance, pricing and cost per sample, the service provider landscape, and future growth opportunities.
The market covers outsourced services for designing, running, and analyzing studies that scan variants across the whole genome for links to diseases, traits, and drug response. Services span array genotyping, low-pass or full genome and exome sequencing, sample handling and QC, imputation against reference panels, association testing, and post-GWAS work such as fine-mapping, annotation, building polygenic risk scores (PRS), Mendelian randomization, and linking results to clinical and multiomic data. Providers include genomics service laboratories, contract research organizations, bioinformatics firms, technology companies, and academic genotyping centers. Sales of arrays, sequencers, and reagents for in-house use, clinical diagnostic testing, and direct-to-consumer genetic testing are excluded.
Our Future Health, the U.K.'s largest health research program, has enrolled more than 2 million consented volunteers and released array data for 755,000 of them, imputed to more than 159 million variants in December 2025, and Eurofins Genomics will genotype as many as 5 million participants at a purpose-built U.K. lab. According to the National Institutes of Health (NIH), the All of Us Research Program had more than 747,000 participants by June 2026, over 86% of them from groups long underrepresented in health research, and the Million Veteran Program of the Department of Veterans Affairs has enrolled more than one million veterans and published an analysis of 2,068 traits across diverse ancestries.
Genetic and health data are highly sensitive, and studies must comply with the EU General Data Protection Regulation (GDPR), U.S. HIPAA rules, and consent and access rules, which add cost and can limit data sharing and slow recruitment; the 2025 bankruptcy and sale of 23andMe sharpened public concern over genetic privacy. Public funding is another restraint, with All of Us receiving about USD 158 million from the National Institutes of Health in FY2025, roughly 71% less than in FY2023. Turning associations into causal genes and clinical use is also difficult, since many variants have small effects, sit in regulatory regions, and are hard to separate because of linkage disequilibrium, while datasets with more than a billion variants demand heavy computing and statistical expertise.
Multi-ancestry studies offer a significant opportunity, as most past GWAS were run in people of European ancestry and diverse cohorts such as All of Us and the Million Veteran Program need specialized genotyping, imputation, and analysis. The shift toward sequencing-based GWAS, which captures rare, structural, and population-specific variants that arrays miss, favors providers with sequencing capacity. Post-GWAS analysis is a higher-value opening, as fine-mapping, colocalization with expression and protein data, Mendelian randomization, and AI-based gene prioritization are needed to explain loci that mostly lie in non-coding regions. Agricultural genotyping for plant and animal breeding adds further demand, especially in Asia-Pacific and Latin America. Key trends include the move from arrays to low-pass and whole-genome sequencing, analysis inside cloud-based trusted research environments such as the All of Us Researcher Workbench, and the integration of GWAS with health records and multiomic data.
By service type, the GWAS services market is segmented into genotyping services, imputation & quality control services, statistical & bioinformatics analysis services, and study design & consulting services. Genotyping services are expected to account for the largest share in 2026, as every study needs genotyping or sequencing, population programs and pharmaceutical studies process very large sample volumes, and contracts such as Eurofins Genomics' work for Our Future Health run to millions of participants. Statistical & bioinformatics analysis services are expected to grow at the highest CAGR, driven by the growing complexity of datasets, rising demand for fine-mapping, PRS, and Mendelian randomization, and the linking of GWAS with health records and multiomic data. Genotyping covers arrays, low-pass sequencing, and whole-genome and exome work, while analysis spans association tests, fine-mapping, risk scores, and Mendelian randomization.
By technology, the GWAS services market is segmented into microarray-based genotyping, sequencing-based genotyping, and other technologies. Microarray-based genotyping is expected to account for the largest share in 2026, owing to cheap per-sample costs, long-standing use in the biggest biobanks, and products built for biobanks such as Illumina Infinium and Thermo Fisher Scientific Axiom arrays; Our Future Health's array covers 686,416 variants before imputation. Sequencing-based genotyping is expected to grow at the highest CAGR, as sequencing costs fall, sequencing picks up rare and structural variants that arrays miss, and programs such as All of Us now hold 535,000 whole-genome sequences. Arrays should stay the most cost-effective choice for the very largest cohorts.
By application, the GWAS services market is segmented into disease association studies & drug target discovery, pharmacogenomics, polygenic risk score development, population & ancestry studies, agricultural genomics, and other applications. Disease association studies & drug target discovery is expected to account for the largest share in 2026, as GWAS is widely used to find genetic risk factors for common and complex diseases and drug developers use the results to identify and validate targets. Polygenic risk score development is expected to grow at the highest CAGR, supported by large biobanks for building and validating scores, health systems testing PRS for screening and prevention, and demand for multi-ancestry scores that work across populations. Pharmacogenomic studies are also growing as drug developers look for genetic factors behind drug response and adverse events.
By end user, the GWAS services market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, biobanks & population health programs, agricultural & animal breeding companies, and other end users. Academic & research institutes are expected to account for the largest share in 2026, as universities run a large part of all GWAS, and they analyze much of the data released by public biobanks. Pharmaceutical & biotechnology companies are expected to grow at the highest CAGR, as drug developers rely more on genetic support for targets, buy into biobank partnerships and data assets, and run more pharmacogenomic work in trials. Biobanks & population health programs, led by All of Us and Our Future Health, also hold a significant share.
North America is set to hold the largest share of the GWAS services market in 2026, owing to large genomics programs, a strong base of drug developers and research institutions, and providers such as Illumina, Thermo Fisher Scientific, and Azenta. In the U.S., All of Us, the Million Veteran Program, and consumer genetic datasets such as 23andMe's, now held by TTAM Research Institute, support research activity, although lower NIH funding may slow publicly funded programs, and Canada contributes through academic research and provincial genomics initiatives. Europe holds a significant share, led by the U.K., where Our Future Health is genotyping millions of participants and UK Biobank remains one of the most widely used GWAS resources, while Finland, through FinnGen, Germany, France, the Netherlands, Denmark, and Sweden contribute through national biobanks.
Asia-Pacific is projected to post the highest CAGR through 2036, owing to expanding national biobanks and precision medicine programs, large and genetically diverse populations, and the need for population-specific data in a field dominated by European-ancestry studies. China is expected to hold the largest share in the region, helped by large cohorts and a strong genomics services industry that includes Novogene, while strong growth is expected in Japan, supported by BioBank Japan, in South Korea, where Macrogen is based, and in Taiwan, Singapore, and India. Latin America and the Middle East & Africa hold smaller shares, with agricultural genomics in Brazil and Argentina and studies of admixed populations supporting Latin America, and the Gulf, where Saudi Arabia, the UAE, and Qatar run national genome programs.
The GWAS services market is moderately fragmented, as genotyping and sequencing technology suppliers, large service labs, CROs, bioinformatics firms, and university genotyping cores all compete for projects. Illumina and Thermo Fisher Scientific supply the leading array platforms, while Eurofins Genomics, LGC Biosearch Technologies, Novogene, Azenta, and Macrogen provide genotyping and sequencing services. Competition centers on cost per sample, capacity for very large cohorts, data quality, turnaround, coverage of diverse populations, imputation and analysis depth, and data security. Leading players are adding high-throughput capacity, low-pass sequencing pipelines, cloud analysis tools, and biobank and pharma partnerships. Recent developments include Eurofins Genomics' genotyping for Our Future Health in a dedicated U.K. laboratory and the 2025 court-approved purchase of 23andMe's assets by TTAM Research Institute.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Eurofins Scientific SE (Eurofins Genomics) (Luxembourg), LGC Limited (Biosearch Technologies) (U.K.), Novogene Co., Ltd. (China), Azenta, Inc. (U.S.), and Macrogen, Inc. (South Korea).
The market covers outsourced services for designing, running, and analyzing studies that scan variants across the whole genome for links to diseases, traits, and drug response. Services span array genotyping, low-pass or full genome and exome sequencing, sample handling and QC, imputation against reference panels, association testing, and post-GWAS work such as fine-mapping, annotation, building polygenic risk scores (PRS), Mendelian randomization, and linking results to clinical and multiomic data. Providers include genomics service laboratories, contract research organizations, bioinformatics firms, technology companies, and academic genotyping centers. Sales of arrays, sequencers, and reagents for in-house use, clinical diagnostic testing, and direct-to-consumer genetic testing are excluded.
Our Future Health, the U.K.'s largest health research program, has enrolled more than 2 million consented volunteers and released array data for 755,000 of them, imputed to more than 159 million variants in December 2025, and Eurofins Genomics will genotype as many as 5 million participants at a purpose-built U.K. lab. According to the National Institutes of Health (NIH), the All of Us Research Program had more than 747,000 participants by June 2026, over 86% of them from groups long underrepresented in health research, and the Million Veteran Program of the Department of Veterans Affairs has enrolled more than one million veterans and published an analysis of 2,068 traits across diverse ancestries.
Market Dynamics
Population-scale biobanks and national genomics programs are the main driver of the GWAS services market, as they produce the large linked genetic and health datasets that well-powered association studies need, and they rely on specialist laboratories for high-throughput genotyping, standardized quality control, and imputation. Drug developers add demand because targets supported by human genetics have better odds in trials, which has led to investment in large studies, biobank partnerships, and genetic data assets; Regeneron's USD 256 million bid for 23andMe, reported in 2025, shows how highly such datasets are valued. PRS development is a growing source of work, as biobank data are used to build and validate scores for coronary artery disease, type 2 diabetes, breast cancer, and other common conditions. Lower costs for arrays, low-pass sequencing, and whole-genome sequencing also make very large studies more affordable.Genetic and health data are highly sensitive, and studies must comply with the EU General Data Protection Regulation (GDPR), U.S. HIPAA rules, and consent and access rules, which add cost and can limit data sharing and slow recruitment; the 2025 bankruptcy and sale of 23andMe sharpened public concern over genetic privacy. Public funding is another restraint, with All of Us receiving about USD 158 million from the National Institutes of Health in FY2025, roughly 71% less than in FY2023. Turning associations into causal genes and clinical use is also difficult, since many variants have small effects, sit in regulatory regions, and are hard to separate because of linkage disequilibrium, while datasets with more than a billion variants demand heavy computing and statistical expertise.
Multi-ancestry studies offer a significant opportunity, as most past GWAS were run in people of European ancestry and diverse cohorts such as All of Us and the Million Veteran Program need specialized genotyping, imputation, and analysis. The shift toward sequencing-based GWAS, which captures rare, structural, and population-specific variants that arrays miss, favors providers with sequencing capacity. Post-GWAS analysis is a higher-value opening, as fine-mapping, colocalization with expression and protein data, Mendelian randomization, and AI-based gene prioritization are needed to explain loci that mostly lie in non-coding regions. Agricultural genotyping for plant and animal breeding adds further demand, especially in Asia-Pacific and Latin America. Key trends include the move from arrays to low-pass and whole-genome sequencing, analysis inside cloud-based trusted research environments such as the All of Us Researcher Workbench, and the integration of GWAS with health records and multiomic data.
Segment Analysis
The report analyzes the market by service type, technology, application, end user, and geography, helping stakeholders identify the most attractive areas for service development, capacity investment, and partnering.By service type, the GWAS services market is segmented into genotyping services, imputation & quality control services, statistical & bioinformatics analysis services, and study design & consulting services. Genotyping services are expected to account for the largest share in 2026, as every study needs genotyping or sequencing, population programs and pharmaceutical studies process very large sample volumes, and contracts such as Eurofins Genomics' work for Our Future Health run to millions of participants. Statistical & bioinformatics analysis services are expected to grow at the highest CAGR, driven by the growing complexity of datasets, rising demand for fine-mapping, PRS, and Mendelian randomization, and the linking of GWAS with health records and multiomic data. Genotyping covers arrays, low-pass sequencing, and whole-genome and exome work, while analysis spans association tests, fine-mapping, risk scores, and Mendelian randomization.
By technology, the GWAS services market is segmented into microarray-based genotyping, sequencing-based genotyping, and other technologies. Microarray-based genotyping is expected to account for the largest share in 2026, owing to cheap per-sample costs, long-standing use in the biggest biobanks, and products built for biobanks such as Illumina Infinium and Thermo Fisher Scientific Axiom arrays; Our Future Health's array covers 686,416 variants before imputation. Sequencing-based genotyping is expected to grow at the highest CAGR, as sequencing costs fall, sequencing picks up rare and structural variants that arrays miss, and programs such as All of Us now hold 535,000 whole-genome sequences. Arrays should stay the most cost-effective choice for the very largest cohorts.
By application, the GWAS services market is segmented into disease association studies & drug target discovery, pharmacogenomics, polygenic risk score development, population & ancestry studies, agricultural genomics, and other applications. Disease association studies & drug target discovery is expected to account for the largest share in 2026, as GWAS is widely used to find genetic risk factors for common and complex diseases and drug developers use the results to identify and validate targets. Polygenic risk score development is expected to grow at the highest CAGR, supported by large biobanks for building and validating scores, health systems testing PRS for screening and prevention, and demand for multi-ancestry scores that work across populations. Pharmacogenomic studies are also growing as drug developers look for genetic factors behind drug response and adverse events.
By end user, the GWAS services market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, biobanks & population health programs, agricultural & animal breeding companies, and other end users. Academic & research institutes are expected to account for the largest share in 2026, as universities run a large part of all GWAS, and they analyze much of the data released by public biobanks. Pharmaceutical & biotechnology companies are expected to grow at the highest CAGR, as drug developers rely more on genetic support for targets, buy into biobank partnerships and data assets, and run more pharmacogenomic work in trials. Biobanks & population health programs, led by All of Us and Our Future Health, also hold a significant share.
Regional Analysis
The report covers North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa, spanning 22 countries and four rest-of-region groups. The regional analysis of the GWAS services market considers biobank and national program activity, pharmaceutical research, public funding, data governance rules, agricultural genomics, and the presence of service providers.North America is set to hold the largest share of the GWAS services market in 2026, owing to large genomics programs, a strong base of drug developers and research institutions, and providers such as Illumina, Thermo Fisher Scientific, and Azenta. In the U.S., All of Us, the Million Veteran Program, and consumer genetic datasets such as 23andMe's, now held by TTAM Research Institute, support research activity, although lower NIH funding may slow publicly funded programs, and Canada contributes through academic research and provincial genomics initiatives. Europe holds a significant share, led by the U.K., where Our Future Health is genotyping millions of participants and UK Biobank remains one of the most widely used GWAS resources, while Finland, through FinnGen, Germany, France, the Netherlands, Denmark, and Sweden contribute through national biobanks.
Asia-Pacific is projected to post the highest CAGR through 2036, owing to expanding national biobanks and precision medicine programs, large and genetically diverse populations, and the need for population-specific data in a field dominated by European-ancestry studies. China is expected to hold the largest share in the region, helped by large cohorts and a strong genomics services industry that includes Novogene, while strong growth is expected in Japan, supported by BioBank Japan, in South Korea, where Macrogen is based, and in Taiwan, Singapore, and India. Latin America and the Middle East & Africa hold smaller shares, with agricultural genomics in Brazil and Argentina and studies of admixed populations supporting Latin America, and the Gulf, where Saudi Arabia, the UAE, and Qatar run national genome programs.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis by key player for 2025, together with company profiles covering business and financial overviews, GWAS services portfolios, strategic developments, and SWOT analyses.The GWAS services market is moderately fragmented, as genotyping and sequencing technology suppliers, large service labs, CROs, bioinformatics firms, and university genotyping cores all compete for projects. Illumina and Thermo Fisher Scientific supply the leading array platforms, while Eurofins Genomics, LGC Biosearch Technologies, Novogene, Azenta, and Macrogen provide genotyping and sequencing services. Competition centers on cost per sample, capacity for very large cohorts, data quality, turnaround, coverage of diverse populations, imputation and analysis depth, and data security. Leading players are adding high-throughput capacity, low-pass sequencing pipelines, cloud analysis tools, and biobank and pharma partnerships. Recent developments include Eurofins Genomics' genotyping for Our Future Health in a dedicated U.K. laboratory and the 2025 court-approved purchase of 23andMe's assets by TTAM Research Institute.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Eurofins Scientific SE (Eurofins Genomics) (Luxembourg), LGC Limited (Biosearch Technologies) (U.K.), Novogene Co., Ltd. (China), Azenta, Inc. (U.S.), and Macrogen, Inc. (South Korea).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global GWAS services market.
- Explains how biobank growth, genetic target discovery, PRS work, and cheaper genotyping drive demand.
- Assesses the impact of data privacy rules, public funding limits, and analysis complexity on the market.
- Identifies high-growth opportunities across service type, technology, application, end user, and region.
- Tracks the shift to sequencing-based GWAS, multi-ancestry studies, and AI-enabled post-GWAS analysis.
- Benchmarks leading companies by capacity, cost per sample, analysis capabilities, and biobank partnerships.
- Supports service planning, capacity investment, partnering, and market entry decisions for providers and investors.
Key Questions Answered
- How big is the global GWAS services market today, and how will it grow through 2036?
- How are population-scale biobanks and national genomics programs shaping demand for GWAS services?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How fast will sequencing-based genotyping replace arrays in large association studies?
- Which service type, technology, application, and end user segments will grow the fastest?
- How will polygenic risk scores and post-GWAS analysis change the value of GWAS projects?
- How do data privacy rules and public funding constraints affect study volumes?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and what strategies are they using?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. GWAS Services Market, by Service Type
6. GWAS Services Market, by Technology
7. GWAS Services Market, by Application
8. GWAS Services Market, by End User
9. GWAS Services Market, by Geography
10. Competitive Landscape
11. Company Profiles
12. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Eurofins Scientific SE
- LGC Limited
- Novogene Co., Ltd.
- Azenta, Inc.
- Macrogen, Inc.
